𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adjuvant immunotherapy of high risk stage I melanoma with transfer factor

✍ Scribed by Myron R. Blume; Ernest H. Rosenbaum; Richard J. Cohen; Jay Gershow; Alan B. Glassberg; Eileen Shepley

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
679 KB
Volume
47
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Adjuvant immunotherapy of primary resect
Adjuvant immunotherapy of primary resected lung cancer with transfer factor
✍ Takehiko Fujisawa; Yutaka Yamaguchi; Hideki Kimura; Masaaki Arita; Masayuki Baba πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 596 KB

One hundred seventy-one patients were studied in order to evaluate the clinical efficacy of the transfer factor (TF) for primary resected lung cancers under a randomized controlled trial. Eligible cases for evaluation were randomly chosen at 75 and 74 patients in TF and control groups, respectively.

The feasibility of adjuvant interferon Ξ±
The feasibility of adjuvant interferon Ξ±-2b in children with high-risk melanoma
✍ Fariba Navid; Wayne L. Furman; Martin Fleming; Bhaskar N. Rao; Sandra Kovach; Ca πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 94 KB

## Abstract ## BACKGROUND It has been shown that induction high‐dose interferon α‐2b (IFN‐α‐2b) followed by maintenance therapy improves recurrence‐free survival in adults with high‐risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnos